Contributions to nephrology
-
Tumor lysis syndrome (TLS) is a constellation of metabolic disturbances that may be observed in patients with malignancies. Clinically significant TLS can occur spontaneously, but most often is seen 48-72 h after initiation of cancer treatment. The metabolic abnormalities observed in patients with TLS include hyperkalemia, hyperuricemia, and hyperphosphatemia, which leads to secondary hypocalcemia. ⋯ Hemodynamic changes reducing glomerular flow due to still undefined mediators are also involved in TLS pathophysiology. Pre-existing volume depletion or renal dysfunction may worsen metabolic derangements and ARF. A good comprehension of TLS pathophysiology has provided the basis for an effective and rational treatment of this complication, adversely affecting the outcome of cancer patients.
-
Review Comparative Study
Hemodynamics of the hemodialysis access: implications for clinical management.
-
Review Comparative Study
Quality assurance and continuous quality improvement programs for vascular access care.
-
Review Comparative Study
Arteriovenous vascular access flow measurement: accuracy and clinical implications.